Vast improvements in oesophageal imaging

Improving the outcomes of oesophageal interventions through novel x-ray based imaging methods

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN11347879

Enrollment

370

Registered

2019-08-20

Start date

2018-10-01

Completion date

Unknown

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oesophageal cancer Cancer

Interventions

This project proposes to use a new imaging technique, called X-Ray Phase Contrast Imaging (XPCI), to improve the detection, staging, treatment and follow-up of oesophageal cancer. XPCI enables the ach

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Males and females over the age of 18 years 2. Ability to provide written, informed consent 3. For stream 1 (biopsies): patients with either suspected Barrett's Oesophagus presenting for endoscopy or patients with documented Barrett's Oesophagus presenting for follow-up endoscopy likely to require a biopsy 4. For stream 2 (endoscopic mucosal resections): patients with early stage oesophageal cancer 5. For stream 3 (oesophagectomy): patients with locally advanced oesophageal cancer which has not metastasised

Exclusion criteria

Exclusion criteria: 1. Patients on anticoagulation undergoing high-risk procedures 2. Patients with esophageal varices that preclude biopsies 3. Patients with known eosinophilic esophagitis 4. Patients that are pregnant 5. Patients with a history of hemostasis disorders (Hemostasis disorders will include, but will not be limited to: patients with hemophilia or other congenitally acquired clotting factor deficiencies, patients with cirrhosis with coagulopathy, patients known to have thrombocytopenia (<100,000 plt/ul) and individuals with von Willibrand’s disease or other known platelet malfunction disorders)

Design outcomes

Primary

Measure	Time frame
Stream 1 patients (biopsies): the number of samples accurately classified as healthy/pre-cancerous lesions, measured using X-Ray Phase Contrast Imaging (XPCI) at the baseline endoscopy Stream 2 patients (endoscopic mucosal resection): the number of samples where the margins of the tumor are correctly identified (with tolerance of 2 mm), measured using X-Ray Phase Contrast Imaging (XPCI) at the baseline endoscopy Stream 3 patients (oesophagectomy): the number of samples where the margins of the tumor are correctly identified (with tolerance of 2 mm), measured using X-Ray Phase Contrast Imaging (XPCI) at the baseline endoscopy	—

Measure

Time frame

Stream 1 patients (biopsies): the number of samples accurately classified as healthy/pre-cancerous lesions, measured using X-Ray Phase Contrast Imaging (XPCI) at the baseline endoscopy Stream 2 patients (endoscopic mucosal resection): the number of samples where the margins of the tumor are correctly identified (with tolerance of 2 mm), measured using X-Ray Phase Contrast Imaging (XPCI) at the baseline endoscopy Stream 3 patients (oesophagectomy): the number of samples where the margins of the tumor are correctly identified (with tolerance of 2 mm), measured using X-Ray Phase Contrast Imaging (XPCI) at the baseline endoscopy

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

United Kingdom

Contacts

Public ContactPaul Wolfson

p.wolfson@ucl.ac.uk+44 (0)2076795055

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026